Actively Recruiting

Age: 1Year +
All Genders
ID06600659

A Pilot Study to Establish Incidence and Characteristics of Patients at Risk for Symptomatic Hyperammonemia Secondary to Recombinant Erwinia Asparaginase

Led by Mayo Clinic · Updated on 2026-02-06

10

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to determine how often patients develop symptomatic hyperammonemia, which means high ammonia levels, when treated with recombinant Erwinia asparaginase. It also seeks to identify which patients are more at risk for this condition. The study focuses on patients with hematopoietic and lymphatic system neoplasms, including acute lymphoblastic leukemia. This is an observational study where patients receive their usual care while researchers collect information. Participants undergo blood sample collection, complete surveys, and have their medical records reviewed to gather data related to their treatment with recombinant Erwinia asparaginase. Participants will be monitored for up to 12 months to track the incidence of hyperammonemia. Throughout the study, researchers will review blood test results, questionnaires, and medical records to understand patient risk factors and outcomes. No treatment is altered for study purposes, and data collection supports understanding the condition's development during therapy.

CONDITIONS

Brief Title

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

Who Can Participate

Age: 1Year +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Followed by pediatric hematology/oncology
  • Receiving recombinant Erwinia asparaginase for treatment of malignancy
  • Age 1 year or older
Not Eligible

You will not qualify if you...

  • Patients younger than 1 year of age
  • Patients who have received recombinant Erwinia asparaginase within the past two weeks

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 12 months

Participants undergo blood sample collection, complete surveys, and have their medical records reviewed to monitor for hyperammonemia.

Visits occur as part of routine clinical care and study assessments

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Referral Office

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Advancing Safe, Comprehensive, Digitally-Enabled Cancer Pain...

Hematopoietic and Lymphoid System Neoplasm

Actively Recruiting

3 locations

Developing a Culturally Informed Patient Navigation Program ...

Hematopoietic and Lymphatic System Neoplasm

Actively Recruiting

2 locations

Walking Juntos: Developing and Testing a Culturally-Tailored...

Hematopoietic and Lymphatic System Neoplasm

Actively Recruiting

77 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here